<DOC>
	<DOCNO>NCT02191865</DOCNO>
	<brief_summary>The primary objective study investigate effect mild ( Child-Pugh A , score 5-6 ) moderate ( Child-Pugh B , score 7-9 ) hepatic impairment pharmacokinetics , safety tolerability nintedanib , comparison control group normal hepatic function follow oral administration nintedanib single dose .</brief_summary>
	<brief_title>Nintedanib Volunteers With Hepatic Impairment Compared With Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Hepatic Insufficiency</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<criteria>Inclusion criterion : Healthy subject : Male female subject , healthy accord investigator 's judgement base complete medical history , include physical examination , vital sign ( BP , PR ) , 12lead ECG , clinical laboratory Age 18 79 year screen visit Hepatically impair patient determine hepatologist/ gastroenterologist : A documented diagnosis impair hepatic function , determine hepatologist/gastroenterologist/specialist internal medicine , must available patient´s source data . Male female chronic hepatically impaired patient determine screen result classify ChildPugh A ( ChildPugh score 56 point ) ChildPugh B ( ChildPugh score 79 point ) . Hepatic insufficiency must diagnose least 3 month screen . Age 18 79 year screen visit Exclusion criterion : Healthy subject : Any find medical examination ( include BP , PR ECG ) deviate normal judge clinically relevant investigator Any laboratory value outside reference range screen visit investigator considers clinical relevance Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder judge clinically relevant investigator Surgery gastrointestinal tract could interfere kinetics trial medication base investigator´s judgment Women breast feed childbearing potential use highly effective method birth control least one month prior inclusion least 3 month administration trial medication . Hepatically impaired patient determined hepatologist/gastroenterologist : Medical disorder , condition history would impair patient 's ability participate complete study opinion investigator sponsor Patients significant disease underlie diagnose hepatic impairment concomitant disease relate . A significant disease define disease opinion investigator : put patient risk participation study may influence result study stable condition Surgery gastrointestinal tract could interfere kinetics trial medication base investigator´s judgment Women breast feed childbearing potential use highly effective method birth control least one month prior inclusion least 3 month administration trial medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>